Islas-Vazquez Lorenzo, Alvarado-Alvarado Yan Carlos, Cruz-Aguilar Marisa, Velazquez-Soto Henry, Villalobos-Gonzalez Eduardo, Ornelas-Hall Gloria, Perez-Tapia Sonia Mayra, Jimenez-Martinez Maria C
Department of Immunology and Research Unit, Institute of Ophthalmology "Conde de Valenciana Foundation", Mexico City 06800, Mexico.
Unidad de Vigilancia Epidemiológica Hospitalaria, Institute of Ophthalmology "Conde de Valenciana Foundation", Mexico City 06800, Mexico.
Vaccines (Basel). 2023 Nov 30;11(12):1787. doi: 10.3390/vaccines11121787.
Abdala is a recently released RBD protein subunit vaccine against SARS-CoV-2. A few countries, including Mexico, have adopted Abdala as a booster dose in their COVID-19 vaccination schemes. Despite that, most of the Mexican population has received full-scheme vaccination with platforms other than Abdala; little is known regarding Abdala's immunological features, such as its antibody production and T- and B-cell-specific response induction. This work aimed to study antibody production and the adaptive cellular response in the Mexican population that received the Abdala vaccine as a booster. We recruited 25 volunteers and evaluated their RBD-specific antibody production, T- and B-cell-activating profiles, and cytokine production. Our results showed that the Abdala vaccine increases the concentration of RBD IgG-specific antibodies. Regarding the cellular response, after challenging peripheral blood cultures with RBD, the plasmablast (CD19+CD27+CD38) and transitional B-cell (CD19+CD21+CD38) percentages increased significantly, while T cells showed an increased activated phenotype (CD3+CD4+CD25+CD69+ and CD3+CD4+CD25+HLA-DR+). Also, IL-2 and IFN-γ increased significantly in the supernatant of the RBD-stimulated cells. Our results suggest that Abdala vaccination, used as a booster, evokes antibody production and the activation of previously generated memory against the SARS-CoV-2 RBD domain.
阿卜杜拉（Abdala）是一种最近获批的针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的受体结合域（RBD）蛋白亚基疫苗。包括墨西哥在内的一些国家已将阿卜杜拉用作其2019冠状病毒病（COVID-19）疫苗接种计划中的加强针。尽管如此，大多数墨西哥人已通过阿卜杜拉以外的疫苗平台完成了全程接种；关于阿卜杜拉的免疫特性，如抗体产生以及T细胞和B细胞特异性反应诱导情况，人们了解甚少。这项研究旨在探讨接种阿卜杜拉疫苗作为加强针的墨西哥人群中的抗体产生情况和适应性细胞反应。我们招募了25名志愿者，评估了他们RBD特异性抗体的产生、T细胞和B细胞激活情况以及细胞因子产生情况。我们的研究结果显示，阿卜杜拉疫苗可提高RBD特异性IgG抗体的浓度。在细胞反应方面，用RBD刺激外周血培养物后，浆母细胞（CD19+CD27+CD38）和过渡性B细胞（CD19+CD21+CD38）的百分比显著增加，而T细胞显示出激活表型增加（CD3+CD4+CD25+CD69+和CD3+CD4+CD25+HLA-DR+）。此外，RBD刺激的细胞上清液中的白细胞介素-2（IL-2）和干扰素-γ（IFN-γ）显著增加。我们的研究结果表明，接种阿卜杜拉疫苗作为加强针可引发抗体产生，并激活先前产生的针对SARS-CoV-2 RBD结构域的记忆反应。
